Safety and efficacy of Sofosbuvir therapy in chronic hepatitis C patients of Peshawar, Khyber Pakhtunkhwa, Pakistan

This study is designed to monitor the rapid virological response (RVR) for 8 weeks and sustained virological response (SVR) for 12 weeks during Sofosbuvir therapy in chronic hepatitis C patients in Peshawar, KPK, Pakistan. A total of 162 hepatitis C positive patients were enrolled in this study. A...

Full description

Bibliographic Details
Main Authors: Muhammad Jawad, Sobia Attaullah, Sanaullah khan, Faheem Ullah, Muhammad Zahid, Faisal Saeed, Ayesha Rizwan, Abdul Wahab
Format: Article
Language:English
Published: Prince of Songkla University 2022-06-01
Series:Songklanakarin Journal of Science and Technology (SJST)
Subjects:
Online Access:https://sjst.psu.ac.th/journal/44-3/13.pdf
Description
Summary:This study is designed to monitor the rapid virological response (RVR) for 8 weeks and sustained virological response (SVR) for 12 weeks during Sofosbuvir therapy in chronic hepatitis C patients in Peshawar, KPK, Pakistan. A total of 162 hepatitis C positive patients were enrolled in this study. After RNA isolation, Quantitative PCR was done to get viral load, and Ohn et al., 1997 protocol were used for hepatitis virus different genotypes. Statistical analysis was performed using SPSS. A Sample t-test was applied to compare gender and age. Chi Square test was applied to compare the RVR and SVR. In total 162 positive hepatitis C patients, 90 were male and 72 were female. High rate 153(94%) of RVR and 158(97%) SVR were achieved during 8 and 12 weeks of sofosbuvir therapy. High SVR and RVR were achieved in the <30 and 31-40 age groups. High EVR 125(99%) by genotype 3 were achieved at 8 weeks of therapy and high SVR 126(100%) by genotype 3 and 28(93%) by genotype 1 were achieved at 12 weeks of sofosbuvir therapy. The current study reveals that high RVR and SVR rates were obtained by shortening the SOF therapy's treatment time up to 8 and 12 weeks. We got a 98.7% response rate at the end of the treatment.
ISSN:0125-3395